Merck Expands Singapore Lab to Meet Asia Pacific Demand for Advanced Biosafety Testing
Merck is expanding its biosafety testing laboratory in Singapore to strengthen services across the Asia Pacific region. The expansion marks a significant milestone for Merck's global testing expertise, which spans over 75 years.
The new lab will offer both Cell Line Characterization services and GMP next-generation sequencing (NGS) capabilities, making it the first BioReliance facility in Asia-Pacific to do so.
Merck's Singapore laboratory was opened in 2018, but the expansion will bring the total lab area to over 1,000 square meters. This investment underscores Merck's commitment to providing industry-leading analytical and biosafety testing services and technical expertise to its customers.
The expanded facility aims to support the industry's move towards state-of-the-art quality control testing of biologics and reduce animal use through advanced molecular methods.
According to Paolo Carli, Head of Advanced Solutions for the Life Science business of Merck, 'Localizing these BioReliance testing capabilities means our Asia Pacific biopharma customers can accelerate their development timelines, improve operational efficiency, and meet evolving regulatory and sustainability standards.'